Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

Ovarian cancer (OC) is the fifth most common cancer in women in developed countries. Despite advances in treatment of epithelial OC: improving techniques and increasing aggressive surgery, the appearance of new cytostatics, targeted drugs, - the overall survival (OS) rates are unsatisfactory (the ov...

Full description

Bibliographic Details
Main Author: S V Khokhlova
Format: Article
Language:Russian
Published: IP Habib O.N. 2017-09-01
Series:Современная онкология
Subjects:
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/27136/pdf
id doaj-8f3533f3522542d896836f760268f4b0
record_format Article
spelling doaj-8f3533f3522542d896836f760268f4b02020-11-25T03:12:26ZrusIP Habib O.N.Современная онкология1815-14341815-14422017-09-01193131824356Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancerS V Khokhlova0N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationOvarian cancer (OC) is the fifth most common cancer in women in developed countries. Despite advances in treatment of epithelial OC: improving techniques and increasing aggressive surgery, the appearance of new cytostatics, targeted drugs, - the overall survival (OS) rates are unsatisfactory (the overall 5-year survival is 38%) and there is still an urgent need in development of new therapeutic agents to improve the results of treatment women with this disease. Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor, which demonstrates the high efficacy of treatment patients with OC associated with mutations in the BRCA genes. And olaparib is approved as a maintenance monotherapy in the treatment of women with platinum sensitive recurrent BRCA-associated OC. This review deals with the information concerning the efficiency and toxicity of olaparib, showing practical guidance on the application. The article focuses on the toxic effects of the drug, which can occur during olaparib therapy, and shows the guidance on management of the disease. Nausea, vomiting, fatigue and anemia are the most commonly reported side effects of olaparib application in clinical studies. Side effects are usually recorded in mild to moderate degree and nondurable. Using proper application and timely monitoring for side effects one can control many toxic actions.https://modernonco.orscience.ru/1815-1434/article/viewFile/27136/pdfbrcaovarian cancerbrcaolaparib
collection DOAJ
language Russian
format Article
sources DOAJ
author S V Khokhlova
spellingShingle S V Khokhlova
Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Современная онкология
brca
ovarian cancer
brca
olaparib
author_facet S V Khokhlova
author_sort S V Khokhlova
title Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
title_short Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
title_full Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
title_fullStr Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
title_full_unstemmed Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
title_sort olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
publisher IP Habib O.N.
series Современная онкология
issn 1815-1434
1815-1442
publishDate 2017-09-01
description Ovarian cancer (OC) is the fifth most common cancer in women in developed countries. Despite advances in treatment of epithelial OC: improving techniques and increasing aggressive surgery, the appearance of new cytostatics, targeted drugs, - the overall survival (OS) rates are unsatisfactory (the overall 5-year survival is 38%) and there is still an urgent need in development of new therapeutic agents to improve the results of treatment women with this disease. Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor, which demonstrates the high efficacy of treatment patients with OC associated with mutations in the BRCA genes. And olaparib is approved as a maintenance monotherapy in the treatment of women with platinum sensitive recurrent BRCA-associated OC. This review deals with the information concerning the efficiency and toxicity of olaparib, showing practical guidance on the application. The article focuses on the toxic effects of the drug, which can occur during olaparib therapy, and shows the guidance on management of the disease. Nausea, vomiting, fatigue and anemia are the most commonly reported side effects of olaparib application in clinical studies. Side effects are usually recorded in mild to moderate degree and nondurable. Using proper application and timely monitoring for side effects one can control many toxic actions.
topic brca
ovarian cancer
brca
olaparib
url https://modernonco.orscience.ru/1815-1434/article/viewFile/27136/pdf
work_keys_str_mv AT svkhokhlova olaparibmaintenancetherapyinpatientswithplatinumsensitiverelapsedovariancancer
_version_ 1724650375415332864